SCHEMBL6525136

SCHEMBL6525136

O=C(Nc1cc(Cl)cc(Cl)c1)Nc1cc(Br)cc(F)c1O.O=C(Nc1ccc(Cl)cc1)Nc1cc(Br)cc(F)c1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.51
MEN1 O00255 9/20 0.51
MAPT P10636 8/20 0.51
LMNA P02545 6/20 0.51
HTT P42858 6/20 0.51
RAB9A P51151 6/20 0.49
NPC1 O15118 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ALDH1A1 P00352 3/20 0.49
GAA P10253 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
GRIK1 P39086 3/20 0.47
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
P2RY1 P47900 1/20 0.46
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341574 0.95 KMT2A (0.53) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4342271 0.94 KMT2A (0.53) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4350043 0.81 NPC1 (0.69) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4345585 0.81 CNR1 (0.56) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4350046 0.80 MEN1 (0.49) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4343284 0.80 EPHX2 (0.58) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4348841 0.79 MEN1 (0.57) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4345977 0.79 LMNA (0.51) KMT2AMEN1MAPTLMNAHTT
SCHEMBL6525140 0.79 KMT2A (0.48) KMT2AMEN1MAPTLMNAHTT
SCHEMBL4347677 0.79 MAPT (0.50) KMT2AMEN1MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KMT2A 2096/4885MEN1 2168/4885MAPT 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.